BICYCLIC TRITERPENOID IRIPALLIDAL AS A NOVEL ANTIGLIOMA AND ANTINEOPLASTIC THERAPY IN VITRO

摘要

This invention relates to a Bicyclic triterpenoid Iripallidal as a novel anti-glioma and anti neoplastic agent, having the composition [()(6R,10S,11S,18R,22S)-26 Hydroxy-22- methylcyloirid-16-enal NSC 631939], wherein it binds to Ras GRP3, a phorbol ester receptor that links DAG/phorbolester signaling with Ras activation and induces phosphorylation of ER K1/2 in a Ras dependent manner, reducing proliferation of cancer cell lines to the extent of 50-70%.